Sectra signed a distribution agreement with RSA Biomedical to offer Sectra CT-based Micromotion Analysis (Sectra CTMA®). This measurement method supports time- and cost-efficient clinical validation of orthopedic implant movement for the benefit of patient safety.
RSA Biomedical provides high-precision products and measurement systems in digital medical imaging across North America, Europe, Australia and Asia.
Sectra CTMA is part of the orthopedic module of Sectra's enterprise imaging solution. It uses CT images taken typically up to two years after implantation to measure 3D movement of an implant or bone fragment on a submillimeter scale. Scientists can then analyze the movement of an implant or bone segment over time. This early high-precision information provides a strong predictor of the long-term survival of the implant.
"Sectra's CT-based measurement method represents a paradigm shift in this field as it contains clear advantages for patients, surgeons and the implant industry. We are excited about the opportunity to help bring this emerging technology to the market," said Per Grundström, President and CEO of RSA Biomedical.
"RSA Biomedical clearly understands what is needed to bring an orthopaedic implant into clinical practice. Its support of the move toward CT-based measurements represents an important step forward in efforts to make this type of validation the new gold standard," said Gustaf Schwang, General Manager Business Unit Orthopaedic Solutions at Sectra.